ARTICLE | Clinical News
GLPG0634: Phase II started
June 13, 2011 7:00 AM UTC
Galapagos began a placebo-controlled, European Phase II trial to evaluate once- and twice-daily GLPG0634 for 4 weeks in 36 RA patients on stable background methotrexate therapy. Galapagos said it plan...